{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:18:04Z","timestamp":1768551484630,"version":"3.49.0"},"reference-count":20,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"unspecified","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor y del Hospital Universitario del Sureste"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease associated with considerable morbidity and mortality, having a significant impact on patient health. Early diagnosis and appropriate treatment play a key role in optimising outcomes. JDM management remains challenging, particularly in severe or refractory cases, due to the limited evidence regarding therapeutic options. Given these challenges, Janus kinase inhibitors, including tofacitinib, have emerged as promising alternatives, yet evidence in paediatric populations is still scarce. We present the case of a child with JDM who achieved sustained remission with tofacitinib monotherapy following the failure of previous therapies. While its use is currently restricted to refractory cases, these findings suggest its potential for earlier integration into treatment algorithms. This work aims to provide valuable insights to guide therapeutic strategies in JDM.<\/jats:p>","DOI":"10.1136\/rmdopen-2025-005651","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T02:40:34Z","timestamp":1747881634000},"page":"e005651","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2198-2071","authenticated-orcid":false,"given":"Delia","family":"Arg\u00fcelles Balas","sequence":"first","affiliation":[{"name":"Paediatric Department, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefan\u00eda","family":"Barral Mena","sequence":"additional","affiliation":[{"name":"Paediatric Department, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M \u00c1ngeles","family":"Mart\u00edn D\u00edaz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-0969","authenticated-orcid":false,"given":"Enrique","family":"Calvo-Aranda","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2025090312480525000_11.2.e005651.1","first-page":"155","article-title":"Dermatomiositis juvenil","volume":"2","author":"Iglesias Jim\u00e9nez","year":"2020","journal-title":"Protoc Diagn Ter Pediatr"},{"key":"2025090312480525000_11.2.e005651.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209247"},{"key":"2025090312480525000_11.2.e005651.3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312480525000_11.2.e005651.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.30475"},{"key":"2025090312480525000_11.2.e005651.5","doi-asserted-by":"crossref","first-page":"152426","DOI":"10.1016\/j.semarthrit.2024.152426","article-title":"Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature","volume":"66","author":"Sener","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312480525000_11.2.e005651.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2025090312480525000_11.2.e005651.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2025090312480525000_11.2.e005651.8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/rheumato4010004","article-title":"A Review of MDA-5 Dermatomyositis and Associated Interstitial Lung Disease","volume":"4","author":"Bhandari","year":"2024","journal-title":"Rheumato"},{"key":"2025090312480525000_11.2.e005651.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03170-z","article-title":"Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025090312480525000_11.2.e005651.10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1756-185X.14258","article-title":"Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"25","author":"Chan Ng","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2025090312480525000_11.2.e005651.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa558"},{"key":"2025090312480525000_11.2.e005651.12","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.820586","article-title":"The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"2025090312480525000_11.2.e005651.13","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain (Bacau)"},{"key":"2025090312480525000_11.2.e005651.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223919"},{"key":"2025090312480525000_11.2.e005651.15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/25785826.2024.2336687","article-title":"Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature","volume":"47","author":"Yamazaki","year":"2024","journal-title":"Immunol Med"},{"key":"2025090312480525000_11.2.e005651.16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090312480525000_11.2.e005651.17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"The Lancet"},{"key":"2025090312480525000_11.2.e005651.18","unstructured":"Assistance Publique - H\u00f4pitaux de Paris . Baricitinib in the treatment of new-onset juvenile dermatomyositis (MYOCIT). ClinicalTrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05524311"},{"key":"2025090312480525000_11.2.e005651.19","doi-asserted-by":"crossref","first-page":"T784","DOI":"10.1016\/j.ad.2023.08.002","article-title":"[Art\u00edculo traducido] Perfil de seguridad a largo plazo y usos fuera de indicaci\u00f3n de los inhibidores de JAK en dermatolog\u00eda","volume":"114","author":"Corbella-Bagot","year":"2023","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"2025090312480525000_11.2.e005651.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac399"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:48:12Z","timestamp":1756928892000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/rmdopen-2025-005651"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005651","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}